Aurinia Pharmaceuticals Inc. (AUPH)Healthcare | Biotechnology | Edmonton, Canada | NasdaqGM
16.03 USD
+0.25
(1.584%)
⇧
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 5:32 a.m. EDT
The immediate outlook is driven by a powerful confluence of insider buying and aggressive speculative positioning. The CEO's purchase of 815,000 shares for $12.5 million serves as a definitive vote of confidence, validating the current price level as a strategic entry point. This internal conviction aligns perfectly with external sentiment, where options flow shows a distinct lack of hedging and a heavy buildup of call contracts at strikes well above the current price. While the statistical forecasting models offer no directional guidance due to their unreliability, the fundamental picture is robust: the company boasts exceptional profitability with nearly 100% profit margins, strong free cash flow, and a balance sheet with minimal debt. The recent price action, which has recovered significantly from the 2024 lows to trade near its 200-day average, suggests the market is re-rating the business quality. With no dividend to complicate the picture, the investment thesis rests entirely on capital appreciation fueled by this strong operational performance and the visible optimism of both management and retail traders. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.031012 |
| AutoETS | 0.031015 |
| AutoARIMA | 0.031015 |
| MSTL | 0.033171 |
| MSTL_115 | 0.045273 |
| MSTL_79 | 0.049816 |
| MSTL_79_115 | 0.077341 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 4.13 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.62 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 12.092 |
| Revenue per Share | 2.247 |
| Market Cap | 2,061,484,928 |
| Trailing P/E | 7.32 |
| Forward P/E | 14.34 |
| Beta | 1.42 |
| Profit Margins | 99.97% |
| Website | https://www.auriniapharma.com |
As of July 11, 2026, 5:32 a.m. EDT: Speculators are heavily positioned for upside, evidenced by massive open interest in out-of-the-money calls (strikes 18, 20, 25) compared to negligible put volume. The call/put ratio is skewed significantly toward bullish exposure, while implied volatility remains compressed on longer-dated strikes, suggesting a low-cost bet on continued appreciation rather than a hedge against downside.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.7830924 |
| Address1 | #140, 14315 – 118 Avenue |
| All Time High | 33.972 |
| All Time Low | 1.41 |
| Ask | 18.38 |
| Ask Size | 1 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.9 - Buy |
| Average Daily Volume10 Day | 2,091,240 |
| Average Daily Volume3 Month | 1,508,608 |
| Average Volume | 1,508,608 |
| Average Volume10Days | 2,091,240 |
| Beta | 1.415 |
| Bid | 13.64 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 4.341 |
| City | Edmonton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 16.03 |
| Current Ratio | 5.548 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 16.14 |
| Day Low | 15.39 |
| Debt To Equity | 12.092 |
| Display Name | Aurinia Pharmaceuticals |
| Earnings Call Timestamp End | 1,772,112,600 |
| Earnings Call Timestamp Start | 1,772,112,600 |
| Earnings Growth | 0.563 |
| Earnings Quarterly Growth | 0.472 |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,785,414,600 |
| Earnings Timestamp Start | 1,785,414,600 |
| Ebitda | 153,712,000 |
| Ebitda Margins | 0.5153 |
| Enterprise To Ebitda | 11.395 |
| Enterprise To Revenue | 5.872 |
| Enterprise Value | 1,751,600,768 |
| Eps Current Year | 0.96 |
| Eps Forward | 1.118 |
| Eps Trailing Twelve Months | 2.19 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 250 708 4345 |
| Fifty Day Average | 15.9928 |
| Fifty Day Average Change | 0.037200928 |
| Fifty Day Average Change Percent | 0.0023261048 |
| Fifty Two Week Change Percent | 78.309235 |
| Fifty Two Week High | 19.25 |
| Fifty Two Week High Change | -3.2199993 |
| Fifty Two Week High Change Percent | -0.16727269 |
| Fifty Two Week Low | 8.55 |
| Fifty Two Week Low Change | 7.4800005 |
| Fifty Two Week Low Change Percent | 0.87485385 |
| Fifty Two Week Range | 8.55 - 19.25 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,409,751,000,000 |
| Float Shares | 126,239,258 |
| Forward Eps | 1.118 |
| Forward P E | 14.338104 |
| Free Cashflow | 124,632,496 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 128 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.78266996 |
| Gross Profits | 233,467,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07532 |
| Held Percent Institutions | 0.60283 |
| Implied Shares Outstanding | 128,601,671 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.isotechnika.com/for_investors/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada. |
| Long Name | Aurinia Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 2,061,484,928 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_882669 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 298,212,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,061,484,786 |
| Number Of Analyst Opinions | 7 |
| Open | 15.71 |
| Operating Cashflow | 166,918,000 |
| Operating Margins | 0.53306997 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Phone | 250 744 2487 |
| Pre Market Change | 0.03999901 |
| Pre Market Change Percent | 0.24952593 |
| Pre Market Price | 16.07 |
| Pre Market Time | 1,784,033,434 |
| Previous Close | 15.78 |
| Price Eps Current Year | 16.697918 |
| Price Hint | 2 |
| Price To Book | 3.6926975 |
| Price To Sales Trailing12 Months | 6.910893 |
| Profit Margins | 0.99973 |
| Quick Ratio | 4.949 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.85714 |
| Region | US |
| Regular Market Change | 0.250001 |
| Regular Market Change Percent | 1.58429 |
| Regular Market Day High | 16.14 |
| Regular Market Day Low | 15.39 |
| Regular Market Day Range | 15.39 - 16.14 |
| Regular Market Open | 15.71 |
| Regular Market Previous Close | 15.78 |
| Regular Market Price | 16.03 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,299,475 |
| Return On Assets | 0.13661 |
| Return On Equity | 0.64983004 |
| Revenue Growth | 0.244 |
| Revenue Per Share | 2.247 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 128,601,671 |
| Shares Percent Shares Out | 0.0746 |
| Shares Short | 9,589,939 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 8,820,725 |
| Short Name | Aurinia Pharmaceuticals Inc |
| Short Percent Of Float | 0.082600005 |
| Short Ratio | 5.19 |
| Source Interval | 15 |
| State | AB |
| Symbol | AUPH |
| Target High Price | 21.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 17.0 |
| Target Median Price | 17.0 |
| Total Cash | 378,524,000 |
| Total Cash Per Share | 2.943 |
| Total Debt | 68,640,000 |
| Total Revenue | 298,295,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.19 |
| Trailing P E | 7.319635 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 14.889925 |
| Two Hundred Day Average Change | 1.1400757 |
| Two Hundred Day Average Change Percent | 0.07656692 |
| Type Disp | Equity |
| Volume | 1,299,475 |
| Website | https://www.auriniapharma.com |
| Zip | T5L 4S6 |